Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. Patients included in the analysis had received ≥1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
Objective
To report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme.
Patients and Methods
Patients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2 weeks. Patients included in the analysis had received ≥1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
Results
A total of 389 patients were enrolled between July 2015 and April 2016, of whom 18% were aged ≥75 years, 6.7% had non-clear cell RCC, 49.6% had bone and 8.2% brain metastases, and 79% had received ≥2 previous lines of therapy. The most common any-grade treatment-related AEs were fatigue (13%) and rash (9%). Twenty-two patients (5.7%) discontinued treatment because of AEs. There were no treatment-related deaths. The objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% confidence interval 3.7-6.2) and the 12-month overall survival rate was 63%. Similar survival rates were reported among patients with non-clear-cell histology, elderly patients, those with bone and/ or brain metastases, and those who had received prior firstline sunitinib or pazopanib, or prior everolimus.
Conclusion
The safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in
Introduction
Nivolumab is a fully human programmed death (PD)-1) immune checkpoint inhibitor antibody, which blocks the interaction between PD-1 expressed on T cells and its ligands PD-L1 and PD-L2, expressed on antigen-presenting cells and cancer cells [1] . Nivolumab therapy induces disruption of PD-1-PD-L1 signalling, restoring the ability of T cells to selectively recognize and kill cancer cells [2] .
In a randomized phase III trial (CheckMate 025) in patients with metastatic RCC (mRCC), nivolumab administered after previous vascular endothelial growth factor (VEGF)-targeted therapy improved the median overall survival (OS) by 5.4 months and had a more favourable safety profile compared with everolimus [3] . This difference was both statistically significant as well as clinically relevant. In November 2015, the US Food and Drug Administration, and in February 2016 the European Medicines Agency, approved nivolumab for patients with mRCC who have received prior anti-angiogenic therapy [4, 5] . A major concern, however, is whether patients enrolled in clinical trials are representative of the overall mRCC patient population. A large number of patients with mRCC do not meet criteria for enrolment in phase III registrative trials, such as those with poor performance status and those with brain metastases, who represent nearly 10% and 15% of patients with mRCC, respectively, after one or more lines of treatment [6, 7] . Additionally, mRCC trials exclude cases with non-clear-cell histologies which represent 15-20% of cases [8, 9] ; thus, little is known about the activity of new agents in these categories of patient.
The Italian Nivolumab Renal Cell Cancer Expanded Access Programme (EAP) was initiated in July 2015, based on the key clinical data described above, while nivolumab was evaluated by the European Medicines Agency and negotiations with the Italian Ministry of Health were ongoing, to address the unmet medical need for patients whose disease progressed after receiving VEGF-targeted therapy.
In the present study, we report the results of patients enrolled in the Italian EAP and seek to evaluate the safety and efficacy of nivolumab in mRCC in a real-world setting.
Patients and Methods

Study Population
Between July 2015 and April 2016 nivolumab was provided by Bristol-Myers Squibb through the EAP to 95 hospitals in Italy. A total of 490 requests were authorized, but 389 patients (80%) ultimately received at least one dose of nivolumab, while most of the remaining 20% of patients experienced further disease progression with clinical deterioration prior to treatment.
Eligible patients were aged ≥18 years and had mRCC that had relapsed after at least one prior anti-angiogenic therapy regimen (including, but not limited to, sunitinib, sorafenib, pazopanib, axitinib, tivozanib and bevacizumab). Prior mammalian target of rapamycin (mTOR) inhibitors and cytokine therapy (e.g. interleukin-2, interferon), vaccine therapy, or treatment with cytotoxic agents were also permitted. There was no limitation on the number of prior treatment regimens allowed. Patients were divided into three risk categories: favourable, intermediate and poor, according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) [10] . Inclusion criteria permitted the presence of asymptomatic brain metastases allowing systemic treatment with corticosteroids equivalent to up to 10 mg daily prednisone. Mildly impaired renal function was allowed, including serum creatinine ≤1.5 9 the upper limit of normal or creatinine clearance ≥40 mL/min. Patients with active autoimmune disease were excluded. Patients with non-clear-cell histologies were also included in the present study through an amendment during the last 3 months of accrual. The study protocol was reviewed and approved by ethics committees. Patients signed and dated a written informed consent form provided by Bristol-Myers Squibb. All data presented were prospectively collected on electronic patient files.
Treatment
Nivolumab 3 mg/kg was administered intravenously every 2 weeks until withdrawal of consent, unacceptable toxicity or disease progression, at the discretion of the physician.
Safety assessments included physical evaluation and laboratory examination the day before every nivolumab administration. Blood tests included haematology, renal and hepatic function, pancreatic enzymes and hormone levels (thyroid function, adrenocorticotropic hormone, cortisol). Data on treatment-related adverse events (AEs), and especially immuno-related AEs, as reported by each treating physician were obtained from patient clinical files and laboratory reports, and classified according to the Common Terminology Criteria for Adverse Events v4.0. Treatment beyond Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined progression was allowed in patients deriving investigator-assessed clinical benefit in the absence of rapid disease progression and tolerating the immunological treatment. A radiographic CT assessment was performed every 3 months and within 6 weeks of original progressive disease to confirm whether there was a decrease or stability in the tumour size or continued progressive disease.
Statistical Analysis
Data were summarized as frequencies for categorical variables and median and range values for continuous variables. Continuous variables were compared using the Wilcoxon test. Associations between categorical variables were assessed using Fisher's exact test, when appropriate. Differences were considered statistically significant when P < 0.05. Progressionfree survival (PFS) was calculated from the start of nivolumab treatment until disease progression or death. Alive patients without progression were censored at the time of last follow-up. OS was calculated from the start of nivolumab treatment until death. Patients lost to follow-up were censored at the time of last contact. The Kaplan-Meier method was used to estimate PFS and OS. The log-rank test and Cox proportional hazards regression were used to test for differences between groups. After univariate analysis, a multivariate analysis was carried out using a Cox regression model. All statistical analyses were performed by an experienced biostatistician with SPSS Statistical Software, version 21.0 (IBM_SPSS, Armonk, NY, USA).
Results
Patients
This analysis included all 389 patients who were enrolled in the EAP at 95 centres in Italy and were treated with ≥1 dose of nivolumab, with a median (range) follow-up of 11.9 (1-24.7) months. Baseline patient characteristics are shown in Table 1 . Patients received a median (range) of 13 (1-49) doses of nivolumab. At the time of the analysis 110 patients (28.3%) were continuing treatment; among the 279 patients (71.7%) who discontinued treatment, the reasons for discontinuation were progressive disease in 213 patients (76.3%), death in 21 (7.5%) and serious AEs in 22 (7.9%).
Safety
Treatment-related AEs are shown in Table 2 . Treatmentrelated grade 3-4 AEs occurred in 27 patients (7%). Of the 22 serious AEs that induced treatment discontinuation, 11 (50%) were considered potentially immuno-related AEs including: grade 4 hyperglycaemia with grade 3 diarrhoea (n = 1); grade 3 pneumonitis (n = 1); grade 3 bronchiolitis obliterans organizing pneumonia, grade 3 asthenia (n = 1,) grade 3 hypertension (n = 1); grade 3 skin toxicity (n = 1); grade 3 tremor (n = 1); grade 2 eyelid ptosis (n = 2); grade 2 liver toxicity (n = 1); and grade 2 hypothyroidism (n = 1). AEs were generally manageable with treatment as per protocolspecific guidelines. No treatment-related deaths were reported.
Tumour Assessment
Response evaluations were available for 355 (91.3%) of 389 included patients, whereas the remaining 34 cases were not assessable as a result of early death (n = 22), early discontinuation attributable to toxicity after a median of 3 cycles (n = 5), loss to follow-up (n = 4), and unspecified reasons (n = 3). The best overall response in the overall patient population was complete response in three patients (0.8%), partial response in 87 (22.4%), stable disease in 124 (31.9%) and progressive disease in 141 (36.2%); thus, the objective response rate (ORR) was 23.1% (90/389) in the overall population and 25.4% (90/355) in patients who had ≥1 response assessment reported. Response rates among patients were irrespective of age, histology, previous lines of (Fig. 1A) . At the time of the analysis, the median OS was not yet reached. The median PFS was 4.4 months (95% CI 3.7-6.2; Fig. 1B ). The median time on therapy was 7.2 months (95% CI 6.1-8.3).
In univariate analysis, age, performance status, IMDC prognostic group and number of prior therapies were found to be significantly associated with OS (Table 4) . Prior firstline treatment with sunitinib or pazopanib did not show any correlation with OS after nivolumab treatment either in the global series ( Figure S1A ) or in cases with second-line nivolumab treatment ( Figure S1B ), whereas prior everolimus showed a borderline association with OS (Table 4) .
In multivariate analysis, age, IMDC score and number of previous lines of treatment all remained predictors of OS (P = 0.04, P < 0.0001 and P = 0.02, respectively; Table 4 ).
Discussion
The treatment of patients with mRCC has undergone great progress in the last 10 years with the arrival of a number of active agents, including, more recently, the immune checkpoint inhibitor nivolumab [3, 11, 12] . These drugs provide new opportunities, but the implication for general practice is largely undocumented [11] . Moreover, patient populations in phase II or III trials may differ from those experienced by physicians in clinical practice [13] . This analysis evaluated the safety and efficacy of nivolumab in patients with mRCC treated in the EAP in Italy.
In this real-life analysis, nivolumab showed satisfactory safety and tolerability, with only 7.9% of patients discontinuing treatment because of serious AEs. We focused on treatmentrelated toxicities and found lower incidences of grade 3-4 AEs (7%) than reported in the CheckMate 025 trial (19%; Table 2 ) [3] . This may be partially explained by a slight underreporting of side effects as patients were treated or even admitted in local hospitals, and these events may not be regularly registered; however, the broad mRCC population in the Italian EAP included 49.6% of patients with bone and/or 8.2% with brain metastases, 79.3% treated from the third-line (Table 1) . These are all subgroups that might be predicted to tolerate therapy less well than patients in the selected population in the phase III trial, which included only 19% of bone metastases and 16% of patients deemed poor risk. In the registration study, patients with brain metastases and those treated in a fourthline setting were not included [3] . Despite this less-defined patient population with poorer prognosis, in the EAP analysis efficacy results of nivolumab for the treatment of mRCC were similar to those of the CheckMate 025 trial [3] . In particular, the ORRs in the EAP and in Checkmate 025 were 23.1% and 25%, respectively; the median PFS was 4.4 and 4.6 months, respectively; median OS was not reached in the EAP; however, the 12-month OS was 63%, which approached the 76% observed in the nivolumab arm of the CheckMate 025 trial. Subgroup analyses showed that the ORR did not differ among the following groups: elderly patients; those with nonclear-cell histologies; different numbers of prior treatment lines; or patients with bone and/or brain metastases (Table 3) . In particular, the cohort of 32 patients with brain metastases was not associated with differences compared with the overall population in terms of ORR (Table 3) , and no association with OS was observed after univariate analysis (Table 4) ; this effect could be explained by cerebral activity of nivolumab as suggested by other authors [14] . Data from the IMDC in patients with mRCC treated with second-line VEGF-targeted therapy showed that patients with non-clear-cell mRCC had a worse ORR than their counterparts with clear-cell RCC (8% vs 12%, respectively) [15] . The 26 cases with mRCC with non-clear-cell histology in our series showed a slightly inferior response rate of 19.2% vs 23.1% of the overall population, suggesting that nivolumab is an active agent for these tumours, even if longer follow-up is needed to obtain mature data on OS. Other authors have recently reported an In a post hoc analysis of the Checkmate 025 study, the impact of baseline characteristics, including prognostic score and prior therapy, on the clinical outcome has been recently evaluated [17] . The median OS was longer in both arms in patients with better IMDC prognostic scores and with prior sunitinib or pazopanib therapy. Moreover, a trend towards better OS for patients treated with nivolumab with prior pazopanib vs sunitinib was observed in the Kaplan-Meier analyses [17] ; however, an interaction test revealed a significant interaction for risk group only but no evidence for other subgroups. In line with these results, in the Italian EAP, IMDC score was the strongest factor able to predict OS, whereas no impact of prior sunitinib or pazopanib was shown (Table 4 and Figure S1A ,B).
In the preliminary exploratory analysis of the French Nivoren study of 528 consecutive patients with mRCC treated with nivolumab as a second or further line of treatment, the authors showed a borderline but statistically significant prognostic impact of previous everolimus (hazard ratio [HR] 1.39, CI 1.01-1.92; P = 0.044), whereas there was no impact of the number of the prior lines measured as >2 vs ≤2 (HR 1.05, CI 0.75-1.48; P = 0.764) [18] . In the Italian EAP, everolimus showed just a trend for inferior OS (HR 1.30, CI 0.95-1.76; P = 0.10), whereas the number of prior lines measured as >1 vs ≤1 showed a statistically significant impact on OS (HR 1.80, CI 1.15-2.87; P = 0.01) that was confirmed in multivariate analysis (Table 4) . Until recently, everolimus has been used as standard of care as a second or further line of therapy. Patients treated with one prior line only did not receive everolimus; therefore, patients treated with nivolumab after everolimus could have a prognostic impact because of more prior lines of therapy received.
Despite the efficacy of nivolumab, a relevant unmet need remains the development of immuno-inflammatory biomarkers able to predict long-term clinical benefit in order to identify which patients with mRCC are likely to have an advantage from this therapy [19] [20] [21] [22] . This is extremely relevant for the management of nivolumab in patients with mRCC with an ORR of 25%, and with long-term survival >4 years in nearly 20% of cases [10, 11] .
This EAP provides extensive real-world experience with nivolumab in patients with previously treated mRCC, including a consistent number of elderly patients and patients with bone metastases, who were poorly represented in the pivotal CheckMate 025 study, and patients with brain metastases and non-clear-cell histotypes, who were not represented at all [3] . Despite these differences, the safety profile and efficacy of nivolumab appeared consistent with that reported in the pivotal trial [3] . Noting the limitations of this type of study, preliminary data from this EAP appear to confirm data from the pivotal trial and suggest that nivolumab is safe and efficacious for the treatment of mRCC in routine clinical practice. 
